Yildiz Yigit, Faculty Member at Health Sciences University and Clinic Chief at Dr. Lütfi Kırdar Training and Research Hospital, shared a post on LinkedIn:
“My highlights from EHA2026:
MPNs: emerging combination approaches with JAK inhibitors, including XPO1 inhibition, aiming for deeper and more durable responses.
Multiple myeloma: advancing liquid biopsy approaches, including circulating tumor cells (CTCs), alongside evolving strategies for sequencing bispecific antibodies and CAR-T therapies.
CAR-T cell therapy: growing interest in next-generation and off-the-shelf approaches (allogeneic CAR-T) aimed at improving accessibility and reducing treatment delays.
Great discussions, new perspectives, and exciting advances shaping the future of hematology.
Looking forward to translating these insights into clinical practice.”
Other articles about EHA OncoDaily.
